Harmony Biosciences

HRMY

Market cap $1.93B

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the fi.

The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?

Five low price-to-book stocks pass our value screens with low P/B, P/S and PEG metrics, highlighting their earnings growth potential.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MEOH, LTM and HRMY made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 14th, 2026.

Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.

Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.

Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.

A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight financial services companies, five healthcare names and four in the information technology sector.